73,779 Shares in Medtronic PLC $MDT Acquired by Walter Public Investments Inc.

Walter Public Investments Inc. bought a new stake in Medtronic PLC (NYSE:MDT) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 73,779 shares of the medical technology company’s stock, valued at approximately $6,366,000. Medtronic comprises approximately 1.5% of Walter Public Investments Inc.’s holdings, making the stock its 27th biggest holding.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. First Command Advisory Services Inc. boosted its holdings in Medtronic by 95.1% in the third quarter. First Command Advisory Services Inc. now owns 1,307 shares of the medical technology company’s stock valued at $114,000 after purchasing an additional 637 shares in the last quarter. Machina Capital S.A.S. acquired a new stake in Medtronic during the third quarter worth approximately $3,904,000. Silver Grove Financial Group Inc. raised its holdings in Medtronic by 18.3% during the third quarter. Silver Grove Financial Group Inc. now owns 1,214 shares of the medical technology company’s stock worth $105,000 after purchasing an additional 188 shares in the last quarter. Davis Investment Partners LLC raised its holdings in Medtronic by 18.5% during the third quarter. Davis Investment Partners LLC now owns 10,254 shares of the medical technology company’s stock worth $885,000 after purchasing an additional 1,602 shares in the last quarter. Finally, Bahl & Gaynor LLC lifted its position in shares of Medtronic by 1.6% during the 3rd quarter. Bahl & Gaynor LLC now owns 36,647 shares of the medical technology company’s stock worth $3,162,000 after buying an additional 565 shares during the last quarter. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Medtronic Trading Up 0.0%

NYSE:MDT opened at $101.64 on Thursday. The company has a market capitalization of $130.01 billion, a PE ratio of 25.03, a P/E/G ratio of 2.38 and a beta of 0.56. Medtronic PLC has a 52-week low of $73.31 and a 52-week high of $106.33. The stock’s 50 day moving average price is $93.34 and its 200 day moving average price is $88.46. The company has a quick ratio of 1.54, a current ratio of 2.07 and a debt-to-equity ratio of 0.50.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, beating analysts’ consensus estimates of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The company had revenue of $9.76 billion during the quarter, compared to analysts’ expectations of $9.55 billion. During the same quarter in the previous year, the business earned $1.26 earnings per share. The firm’s revenue for the quarter was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, research analysts anticipate that Medtronic PLC will post 5.98 EPS for the current year.

Medtronic Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, October 16th. Stockholders of record on Friday, September 25th were issued a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend was Friday, September 25th. Medtronic’s payout ratio is presently 70.94%.

Analysts Set New Price Targets

Several brokerages have recently issued reports on MDT. Needham & Company LLC restated a “buy” rating on shares of Medtronic in a report on Thursday, September 17th. Wall Street Zen upgraded shares of Medtronic from a “hold” rating to a “buy” rating in a research note on Sunday. Deutsche Bank reiterated a “hold” rating and set a $92.00 price target on shares of Medtronic in a research note on Thursday, September 3rd. Robert W. Baird boosted their price target on shares of Medtronic from $91.00 to $100.00 and gave the company a “neutral” rating in a research report on Wednesday, September 2nd. Finally, TD Cowen restated a “buy” rating and issued a $110.00 price objective on shares of Medtronic in a research note on Wednesday, September 30th. Eighteen research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Medtronic has a consensus rating of “Moderate Buy” and an average target price of $102.88.

Insider Activity

In related news, CEO Geoffrey Martha sold 50,000 shares of the stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $95.00, for a total transaction of $4,750,000.00. Following the completion of the sale, the chief executive officer owned 277,866 shares in the company, valued at $26,397,270. This represents a 15.25% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Harry Kiil sold 1,483 shares of the stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total transaction of $138,882.95. Following the sale, the executive vice president owned 42,186 shares of the company’s stock, valued at approximately $3,950,718.90. This represents a 3.40% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 61,903 shares of company stock valued at $5,889,203 in the last ninety days. 0.27% of the stock is currently owned by company insiders.

Recent Medtronic Headlines

These are some of the MDT headlines that stood out recently:

• Positive Sentiment: Medtronic launched a micro guidewire for neurovascular procedures, expanding its product offering in that market. Article: Medtronic launches micro guidewire for neurovascular procedures
• Neutral Sentiment: A collaborative cardiac-therapy trial involving Medtronic has completed enrollment with 349 patients. Results are expected to be presented at Heart Rhythm Society 2027; a planned FDA submission depends on positive data, so the potential benefit remains uncertain. Article: Orchestra BioMed Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
• Negative Sentiment: Medtronic initiated two Class II recalls affecting cardiac products. The OmniaSecure 3930M lead recall cites possible difficulties with fixation during implantation, while a CareLink SmartSync Programmer software issue may cause inaccurate estimates of implanted-device battery life. The recalls raise potential concerns about product reliability and could create costs or reputational risk, although the reports do not quantify their financial impact. Article: What Is Medtronic Facing After Two Class II Cardiac Device Recalls?

Medtronic Company Profile

Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products. The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.